[Recommendations About Multiple Sclerosis Management During Pregnancy, Partum and Post-Partum: Consensus Position of The Portuguese Multiple Sclerosis Study Group and The Portuguese Society of Obstetrics and Maternal-Fetal Medicine].
暂无分享,去创建一个
J. de Sá | J. Cerqueira | S. Batista | L. Sousa | R. Pedrosa | M. Sá | A. M. Silva | R. Simões | P. Abreu | J. Pinheiro | Elsa Dias | Carlos Veríssimo | J. Vale
[1] Jeffrey A. Cohen,et al. Applying the 2017 McDonald diagnostic criteria for multiple sclerosis – Authors' reply , 2018, The Lancet Neurology.
[2] D. Ogunyemi,et al. Multiple sclerosis in pregnancy: prevalence, sociodemographic features, and obstetrical outcomes , 2018, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[3] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[4] M. Filippi,et al. Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning , 2016, Multiple sclerosis.
[5] M. Trojano,et al. History of multiple sclerosis in 2 successive pregnancies , 2016, Neurology.
[6] S. Tavakolpour,et al. New Insights into the Management of Patients with Autoimmune Diseases or Inflammatory Disorders During Pregnancy , 2016, Scandinavian journal of immunology.
[7] M. Wenten,et al. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study , 2016, BMC Neurology.
[8] Shin C. Beh,et al. Neurotherapeutic Strategies for Multiple Sclerosis. , 2016, Neurologic clinics.
[9] A. Ascherio,et al. Vitamin D Status During Pregnancy and Risk of Multiple Sclerosis in Offspring of Women in the Finnish Maternity Cohort. , 2016, JAMA neurology.
[10] A. Ascherio,et al. Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update , 2016, Seminars in Neurology.
[11] A. Langer-Gould,et al. Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility , 2016, PloS one.
[12] P. Coyle. Management of women with multiple sclerosis through pregnancy and after childbirth , 2016, Therapeutic advances in neurological disorders.
[13] C. Binns,et al. The Long-Term Public Health Benefits of Breastfeeding , 2016, Asia-Pacific journal of public health.
[14] C. Pozzilli,et al. Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis , 2015, Multiple sclerosis.
[15] M. Magyari. Role of socio‐economic and reproductive factors in the risk of multiple sclerosis , 2015, Acta neurologica Scandinavica.
[16] S. Vukusic,et al. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis , 2015, Multiple sclerosis.
[17] S. Vukusic,et al. Multiple sclerosis and pregnancy in the 'treatment era' , 2015, Nature Reviews Neurology.
[18] P. Touraine,et al. Fecundity in women with multiple sclerosis: an observational mono-centric study , 2015, Journal of Neurology.
[19] G. Koren,et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study , 2015, Multiple sclerosis.
[20] T. Kauko,et al. Multiple sclerosis and vitamin D during pregnancy and lactation , 2015, Acta neurologica Scandinavica.
[21] R. Gold,et al. Serum anti-Müllerian hormone levels in reproductive-age women with relapsing–remitting multiple sclerosis , 2015, Multiple sclerosis.
[22] P. Mccombe,et al. Multiparity in women with multiple sclerosis causes less long-term disability: No , 2014, Multiple sclerosis.
[23] J. De Keyser,et al. Multiparity in women with multiple sclerosis causes less long-term disability: Yes , 2014, Multiple sclerosis.
[24] M. Hutchinson. Multiparity in women with multiple sclerosis causes less long-term disability: Commentary , 2014, Multiple sclerosis.
[25] F. Salvi,et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. , 2014, Fertility and sterility.
[26] R. Gold,et al. Natalizumab use during the third trimester of pregnancy. , 2014, JAMA neurology.
[27] J. Lechner-Scott,et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis , 2014, Multiple sclerosis.
[28] T. Olsson,et al. Reverse causality behind the association between reproductive history and MS , 2014, Multiple sclerosis.
[29] Yinshan Zhao,et al. Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs , 2014, CNS Drugs.
[30] R. Bove,et al. Neuroradiology in Women of Childbearing Age , 2014, Continuum.
[31] A. Synnes,et al. A Review of Safety-Related Pregnancy Data Surrounding the Oral Disease-Modifying Drugs for Multiple Sclerosis , 2014, CNS Drugs.
[32] C. Pozzilli,et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[33] J. Correale,et al. Artificial reproductive techniques in multiple sclerosis. , 2013, Clinical immunology.
[34] A. Langer-Gould,et al. Effects of pregnancy and breastfeeding on the multiple sclerosis disease course. , 2013, Clinical immunology.
[35] C. Wolfson,et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review , 2013, BMC Neurology.
[36] C. Kolb,et al. Multiple sclerosis and pregnancy: therapeutic considerations , 2013, Journal of Neurology.
[37] A. Sadovnick,et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS) , 2013, Multiple sclerosis.
[38] Y. Fragoso,et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis , 2013, Clinical Neurology and Neurosurgery.
[39] B. Cree. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis , 2013, Multiple sclerosis.
[40] C. Pozzilli,et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study , 2012, BMC Neurology.
[41] J. Lünemann,et al. The initiation and prevention of multiple sclerosis , 2012, Nature Reviews Neurology.
[42] J. Correale,et al. Increase in multiple sclerosis activity after assisted reproduction technology , 2012, Annals of neurology.
[43] V. Davoudi,et al. Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy , 2012, European Neurology.
[44] R. Gold,et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany , 2012, Therapeutic advances in neurological disorders.
[45] R. Pedrosa,et al. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis , 2012, Journal of the Neurological Sciences.
[46] M. Clanet,et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[47] G. Giovannoni,et al. Breastfeeding and multiple sclerosis relapses: a meta-analysis , 2012, Journal of Neurology.
[48] K. Dear,et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event , 2012, Neurology.
[49] D. Pelletier,et al. Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort , 2012, Multiple sclerosis.
[50] C. Pozzilli,et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis , 2011, Neurology.
[51] A. Synnes,et al. Neonatal and Delivery Outcomes in Women with Multiple Sclerosis , 2011, Annals of neurology.
[52] A. Finkelsztejn,et al. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta‐analysis of the literature , 2011, BJOG : an international journal of obstetrics and gynaecology.
[53] G. Ebers,et al. Congenital Abnormalities and Multiple Sclerosis , 2010, BMC neurology.
[54] M. Boggild,et al. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes , 2010, Journal of Neurology.
[55] L. Airas,et al. Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland , 2010, Multiple sclerosis.
[56] A. Sadovnick,et al. No Effect of Parental Age on Risk of Multiple Sclerosis: A Population-Based Study , 2009, Neuroepidemiology.
[57] S. Vukusic,et al. The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: Rationale, objectives and state of advancement , 2009, Journal of the Neurological Sciences.
[58] T. Trikalinos,et al. A summary of the Agency for Healthcare Research and Quality's evidence report on breastfeeding in developed countries. , 2009, Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.
[59] W. Engel,et al. INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL , 2009, Neurology.
[60] R. Gold,et al. Increase in Relapse Rate during Assisted Reproduction Technique in Patients with Multiple Sclerosis , 2008, European Neurology.
[61] P. Butow,et al. The motherhood choice: Themes arising in the decision-making process for women with multiple sclerosis , 2008, Multiple sclerosis.
[62] P. Butow,et al. The motherhood choice: a decision aid for women with multiple sclerosis. , 2008, Patient education and counseling.
[63] F. Fazekas,et al. Intravenous immunoglobulin in MS: Promise or failure? , 2007, Journal of the Neurological Sciences.
[64] O. Hommes,et al. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis , 2007, Multiple sclerosis.
[65] U. Zettl,et al. Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis , 2006, Journal of Neurology.
[66] N. Gilhus,et al. Planned vaginal births in women with multiple sclerosis: delivery and birth outcome , 2006, Acta neurologica Scandinavica. Supplementum.
[67] E. Leray,et al. Increase in multiple sclerosis relapse rate following in vitro fertilization , 2006, Neurology.
[68] Miguel A Hernán,et al. Recent use of oral contraceptives and the risk of multiple sclerosis. , 2005, Archives of neurology.
[69] P. Vermersch,et al. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis , 2004, Multiple sclerosis.
[70] A. Achiron,et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis , 2004, Journal of Neurology.
[71] P. Ragonese,et al. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study , 2004, Acta neurologica Scandinavica.
[72] P. Sørensen. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials , 2003, Neurological Sciences.
[73] Seth E. Bouvier,et al. Treatment of multiple sclerosis with the pregnancy hormone estriol , 2002, Annals of neurology.
[74] H. Ford,et al. Multiple sclerosis and pregnancy , 2002, Postgraduate medical journal.
[75] B. Mueller,et al. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. , 2002, American journal of obstetrics and gynecology.
[76] D Spiegelman,et al. Oral contraceptives and the incidence of multiple sclerosis , 2000, Neurology.
[77] M. Hutchinson,et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. , 1999, The New England journal of medicine.
[78] G. Comi. Early treatment , 2006, Neurological Sciences.